A phase 2 clinical trial for the Treatment of the Symptoms of Neurodegenerative Diseases
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Cannabidiol (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease
- Focus Therapeutic Use
- Acronyms NEUROBIS
- 14 Oct 2024 New trial record
- 08 Oct 2024 According to Avextra media release, The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS clinicsl trial.
- 08 Oct 2024 According to Avextra media release, this study is funded by Bando Ricerca Finalizzata through a grant from the Italian Ministry of Health signifying the support of regulators in gathering of clinical evidence for Cannabis-based medicines. The principal investigator of this trial is Prof. Dr. Letizia Mazzini